Triple-negative breast cancer generally benefits from neoadjuvant chemotherapy. Neoadjuvant chemotherapy for triple-negative breast cancer turns locally advanced inoperable breast cancer into operable, and for early stage breast cancer with large tumors and a need for breast conservation, neoadjuvant chemotherapy turns non-breast-conserving breast cancer into breast-conserving. Traditional neoadjuvant regimens for triple-negative breast cancer include anthracycline-ethyl ester acid chemotherapy drugs, paclitaxel drugs, which are also effective for triple-negative breast cancer, and platinum drugs and cisplatin neoadjuvant chemotherapy, which are more effective in triple-negative breast cancer. Usually triple-negative breast cancer is more sensitive to neoadjuvant chemotherapy than non-triple-negative breast cancer, and with neoadjuvant chemotherapy, some patients are able to achieve complete pathological remission. During the treatment period it is also important to monitor changes in blood counts and liver and kidney function indicators, as many are prone to secondary myelosuppression, and patients may also experience significant weakness, loss of appetite, nausea, and vomiting. During the treatment period, patients should increase dietary nutrition, eat more light food, stay away from fried food and greasy food, and have appropriate physical exercise.